ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 871 • 2019 ACR/ARP Annual Meeting

    ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry

    Zachary Wallace1, Huifeng Yun 2, Jeffrey Curtis 2, Shuo Yang 2, Lang Chen 2, John Stone 3 and Hyon K. Choi 4, 1Massachusetts General Hospital, Boston, 2University of Alabama at Birmingham, Birmingham, AL, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Boston, MA

    Background/Purpose: The management of ANCA-associated vasculitis (AAV) evolved substantially in recent years because of evidence supporting the efficacy of various treatment regimens.  As such, treatment…
  • Abstract Number: 1688 • 2019 ACR/ARP Annual Meeting

    Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial

    Benjamin Terrier1, Jonathan London 2, Fabrice Bonnet 3, Diane Cerutti 4, Nathalie Costedoat-Chalumeau 5, Elisabeth Diot 6, Yasmina Ferfar 7, Aurélie Hummel 8, Gilles Kaplanski 9, Isabelle Marie 10, Thomas Quémeneur 11, Patricia Rullier 12, Patricia Senet 13, Noémie Le Gouellec 14, Julie Lejeune 7, David Saadoun 15 and Patrice Cacoub 15, 1National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, 2Croix Saint-Simon Hospital, Paris, France, 3CHU, Bordeaux, France, 4CH, Toulon, France, 5Cochin University Hospital, Paris, France, 6APHP, Tours, France, 7Pitié-Salpétrière Hospital, Paris, France, 8APHP, Paris, France, 9CHU, Marseille, France, 10CHU, Rouen, France, 11CH Valenciennes, Valenciennes, France, 12CHU, Montpellier, France, 13Tenon Hospital, Paris, France, 14CH, Valenciennes, France, 15AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France

    Background/Purpose: A previous retrospective study suggested superiority of glucocorticoids (GCs) plus rituximab (RTX) compared to GCs alone to induce complete clinical response in non-infectious cryoglobulinemia…
  • Abstract Number: 2635 • 2019 ACR/ARP Annual Meeting

    Accuracy of Self-Reported Diagnosis of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

    Tanaz Kermani1, Jason Springer 2, Antoine Sreih 3, Dianne Shaw 4, Kalen Young 5, Cristina Burroughs 6 and Peter Merkel 3, 1University of California Los Angeles, Los Angeles, CA, 2Kansas University Medical Center, Kansas, MO, 3University of Pennsylvania, Philadelphia, PA, 4Vasculitis Foundation, North Carolina, 5Vasculitis Foundation, Kansas City, MO, 6University of South Florida, Tampa, FL

    Background/Purpose: To determine the reliability of self-reported diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with…
  • Abstract Number: 873 • 2019 ACR/ARP Annual Meeting

    Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database

    Sebastian E. Sattui1, Zafir Abutalib 2, Jackie Finik 2 and Robert Spiera 3, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, New York, NY, New York, NY, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: Pulmonary involvement, including pulmonary vascular disease and interstitial lung disease can be an important cause of morbidity and even mortality in patients with primary…
  • Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting

    Efficacy of Leflunomide for Treatment of Vasculitis

    NOURA MUSTAPHA 1, Lillian Barra 2, Simon Carette 3, David Cuthbertson 4, Nader A. Khalidi 5, Curry L. Koening 6, Carol Langford 7, Carol McAlear 8, Nataliya Milman 9, Larry Moreland 10, Paul Monach 11, Philip Seo 12, Ulrich Specks 13, Antoine Sreih 14, Steven Ytterberg 13, Peter Merkel 14, Christian Pagnoux15, CanVasc Canadian Vasculitis Research Network 16 and VCRC Vasculitis Clinical Research Consortium 8, 1Hopital Notre Dame, Montreal, QC, Canada, 2St Joseph's health care, London, Canada, 3Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6University of Utah Hospital, Salt Lake City, UT, 7Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania, Division of Rheumatology, Philadelphia, 9Arthritis Centre at the Ottawa Hospital, Riverside Campus, Ottawa, Canada, 10University of Pittsburgh, PITTSBURGH, PA, 11Brigham and Women's Hospital, Boston, MA, 12Johns Hopkins Medicine, Baltimore, MD, 13Mayo Clinic College of Medicine, Rochester, MN, 14University of Pennsylvania, Philadelphia, PA, 15Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 16Mount Sinai Hospital, Vasculitis clinic, toronto, ON, Canada

    Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…
  • Abstract Number: 2638 • 2019 ACR/ARP Annual Meeting

    The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis

    Irena Doubelt1, David Cuthbertson 2, Gunnar Tomasson 3, Simon Carette 1, Nader A. Khalidi 4, Curry L. Koening 5, Carol Langford 6, Carol A. McAlear 7, Larry W. Moreland 8, Paul Monach 9, Philip Seo 10, Ulrich Specks 11, Antoine Sreih 12, Kalen Young 13, Steven Ytterberg 11, Peter A. Merkel 14, Christian Pagnoux 1 and VCRC Vasculitis Clinical Research Consortium 15, 1Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 2University of South Florida, Tampa, FL, 3Faculty of Medicine, University of Iceland and Landpitali University Hospital, Reykjavik, Iceland, 4McMaster University, Hamilton, ON, Canada, 5University of Utah Hospital, Salt Lake City, UT, 6Cleveland Clinic, Cleveland, OH, 7University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, 8University of Pittsburgh, Pittsburgh, PA, 9Brigham and Women's Hospital, Boston, MA, 10Johns Hopkins Medicine, Baltimore, MD, 11Mayo Clinic College of Medicine, Rochester, MN, 12University of Pennsylvania, Philadelphia, PA, 13Vasculitis Foundation, Kansas City, MO, 14Univeristy of Pennsylvania, Philadelphia, PA, 15University of Pennsylvania, Division of Rheumatology, philadelphia

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma and other manifestations of vasculitis, some of which can be life-threatening, cause major organ damage,…
  • Abstract Number: 966 • 2019 ACR/ARP Annual Meeting

    Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients

    Laura van Dam1, Jelle Oskam 2, Sylvia Kamerling 2, Eline Arends 2, Edwin Bredewold 2, Magda Berkowska 2, Jacques van Dongen 2, Ton Rabelink 2, Cees van Kooten 2 and Onno Teng 2, 1LUMC, Leiden, Zuid-Holland, Netherlands, 2LUMC, Leiden, Netherlands

    Background/Purpose: Background: B-cell depletion with rituximab (RTX) is an effective treatment for ANCA-associated vasculitis (AAV) patients. Repeated RTX upon B-cell repopulation or return of ANCAs…
  • Abstract Number: 1712 • 2019 ACR/ARP Annual Meeting

    Head and Neck Involvement of IgA Vasculitis: A Case-Control Study

    Michel Villatoro-Villar1, David Wetter 1, Cynthia Crowson 2, Kenneth Warrington 1 and Matthew Koster 1, 1Mayo Clinic Rochester, Rochester, MN, 2Mayo Clinic Rochester, Rochester

    Background/Purpose: IgA vasculitis (IgAV) is an immune-complex mediated, small-vessel vasculitis which predominantly involves the skin on the lower extremities. Head and neck involvement is rarely…
  • Abstract Number: 2641 • 2019 ACR/ARP Annual Meeting

    Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis

    Jason Springer1, Tanaz Kermani 2, Antoine Sreih 3, Dianne Shaw 4, Kalen Young 5, Cristina Burroughs 6 and Peter Merkel 3, 1Kansas University Medical Center, Kansas, MO, 2University of California Los Angeles, Los Angeles, CA, 3University of Pennsylvania, Philadelphia, PA, 4Vasculitis Foundation, North Carolina, 5Vasculitis Foundation, Kansas City, MO, 6University of South Florida, Tampa, FL

    Background/Purpose: To provide a feasible and sustainable platform for conducting patient-centered research in vasculitis, a prospective, international, internet-based registry of patients with vasculitis has been…
  • Abstract Number: 970 • 2019 ACR/ARP Annual Meeting

    New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction

    Emilie Chan1, Susan Hartzell 2, Lisa Anderson 2, Chiara Cantarelli 2, Chiara Guglielmo 2, Ioannis Tassiulas 3, Sofia Andrighetto 2, Andrea Angeletti 4, Joaquin Manrique Escola 5 and Paolo Cravedi 2, 1Mount Sinai Hospital, New York, NY, 2Mount Sinai Hospital, New York, 3Icahn School of Medicine, New York, 4Sant'Orsola-Malpighi Hospital, Bologna, Italy, 5Complejo Hospital de Navarra, Pamplona, Spain

    Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by the production of auto-antibodies and can be treated with rituximab, a B cell-depleting agent. Despite this, limited data…
  • Abstract Number: 1713 • 2019 ACR/ARP Annual Meeting

    Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase

    CAMILLE RASMUSSEN1, MYLENE TISSEYRE 2, JULIE GARON-CZMIL 2, MARINA ATZENHOFFER 3, Loïc Guillevin 4, LAURENT CHOUCHANA 2 and Benjamin Terrier 4, 1Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, PARIS, PARIS, France, 2PHARMACOVIGILANCE, COCHIN HOSPITAL, PARIS, PARIS, France, 3PHARMACOVIGILANCE CENTER LYON, FRANCE, LYON, France, 4National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France

    Background/Purpose: IgA vasculitis (IgAV) is an immune complex small-vessel vasculitis, with IgA1-dominant immune deposits. Drug-induced IgAV were rarely reported in the literature, but no systematic…
  • Abstract Number: 2689 • 2019 ACR/ARP Annual Meeting

    GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis

    Maria C. Cid1, Rohan Gandhi 2, Marc Corbera-Bellalta 3, Nekane Terrades-Garcia 3, Sujatha Muralidharan 4 and John F Paolini 5, 1Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, 2Kiniksa Pharmaceuticals Corp., san diego, CA, 3Vasculitis Research Unit, Department of Autoimmune Diseases, University of Barcelona, Barcelona, Spain, 4Kiniksa Pharmaceuticals Corp., lexington, MA, 5Kiniksa Pharmaceuticals Corp, lexington, MA

    Background/Purpose: Giant Cell Arteritis (GCA) is a type of large vessel vasculitis that can cause blindness and aortic aneurysms. A significant unmet medical need remains…
  • Abstract Number: 1089 • 2019 ACR/ARP Annual Meeting

    Causes of Death in ANCA-Associated Vasculitis According to ANCA Type

    Zachary Wallace1, Xiaoqing Fu 1, Tyler Harkness 1, John Stone 2, Yuqing Zhang 3 and Hyon K. Choi 3, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Boston, MA

    Background/Purpose: Survival has improved in ANCA-associated vasculitis (AAV) with evolving management strategies, but patients remain at an increased risk of death compared to the general…
  • Abstract Number: 1718 • 2019 ACR/ARP Annual Meeting

    Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017

    Alicia Rodriguez-Pla1, 1University of Arizona/Banner Health Medical Center, Tucson, AZ

    Background/Purpose: Earlier diagnosis and less toxic immunosuppressive therapies have improved the survival of patients with vasculitis. Current data on mortality rates of vasculitis are limited.…
  • Abstract Number: 2790 • 2019 ACR/ARP Annual Meeting

    Platelet Mediates Neutrophil Extracellular Traps Formation via TLR Signaling in ANCA-associated Vasculitis

    Kotaro Matsumoto1, Hidekata Yasuoka 2, Katsuya Suzuki 1 and Tsutomu Takeuchi 1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine, Shinjuku-ku, Aichi, Japan

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an autoimmune disease that affects small- to medium-sized blood vessels and causes vascular inflammation and multiple organ…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology